Literature DB >> 24607504

A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.

Bridget P Keenan1, Yvonne Saenger2, Michel I Kafrouni3, Ashley Leubner3, Peter Lauer4, Anirban Maitra5, Agnieszka A Rucki3, Andrew J Gunderson6, Lisa M Coussens6, Dirk G Brockstedt4, Thomas W Dubensky4, Raffit Hassan7, Todd D Armstrong3, Elizabeth M Jaffee8.   

Abstract

BACKGROUND & AIMS: Premalignant lesions and early stage tumors contain immunosuppressive microenvironments that create barriers for cancer vaccines. Kras(G12D/+);Trp53(R172H/+);Pdx-1-Cre (KPC) mice, which express an activated form of Kras in pancreatic tissues, develop pancreatic intraepithelial neoplasms (PanIN) that progress to pancreatic ductal adenocarcinoma (PDA). We used these mice to study immune suppression in PDA.
METHODS: We immunized KPC and Kras(G12D/+);Pdx-1-Cre mice with attenuated intracellular Listeria monocytogenes (which induces CD4(+) and CD8(+) T-cell immunity) engineered to express Kras(G12D) (LM-Kras). The vaccine was given alone or in sequence with an anti-CD25 antibody (PC61) and cyclophosphamide to deplete T-regulatory (Treg) cells. Survival times were measured; pancreatic and spleen tissues were collected and analyzed by histologic, flow cytometry, and immunohistochemical analyses.
RESULTS: Interferon γ-mediated, CD8(+) T-cell responses were observed in KPC and Kras(G12D/+);Pdx-1-Cre mice given LM-Kras, but not in unvaccinated mice. Administration of LM-Kras to KPC mice 4-6 weeks old (with early stage PanINs), depleted of Treg cells, significantly prolonged survival and reduced PanIN progression (median survival, 265 days), compared with unvaccinated mice (median survival, 150 days; P = .002), mice given only LM-Kras (median survival, 150 days; P = .050), and unvaccinated mice depleted of Treg cells (median survival, 170 days; P = .048). In 8- to 12-week-old mice (with late-stage PanINs), LM-Kras, alone or in combination with Treg cell depletion, did not increase survival time or slow PanIN progression. The combination of LM-Kras and Treg cell depletion reduced numbers of Foxp3(+)CD4(+) T cells in pancreatic lymph nodes, increased numbers of CD4(+) T cells that secrete interleukin 17 and interferon γ, and caused CD11b(+)Gr1(+) cells in the pancreas to acquire an immunostimulatory phenotype.
CONCLUSIONS: Immunization of KPC mice with Listeria monocytogenes engineered to express Kras(G12D), along with depletion of Treg cells, reduces progression of early stage, but not late-stage, PanINs. This approach increases infiltration of the lesion with inflammatory cells. It might be possible to design immunotherapies against premalignant pancreatic lesions to slow or prevent progression to PDA.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Immunity; Listeria Vaccine; Pancreatic Cancer; Tumor Microenvironment

Mesh:

Substances:

Year:  2014        PMID: 24607504      PMCID: PMC4035450          DOI: 10.1053/j.gastro.2014.02.055

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  45 in total

1.  Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16.

Authors:  G R Gunn; A Zubair; C Peters; Z K Pan; T C Wu; Y Paterson
Journal:  J Immunol       Date:  2001-12-01       Impact factor: 5.422

2.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.

Authors:  Paolo P Provenzano; Carlos Cuevas; Amy E Chang; Vikas K Goel; Daniel D Von Hoff; Sunil R Hingorani
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

3.  High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients.

Authors:  Friedrich H Schmitz-Winnenthal; Christine Volk; Kaspar Z'graggen; Luis Galindo; Daniel Nummer; Yvonne Ziouta; Marianna Bucur; Jürgen Weitz; Volker Schirrmacher; Markus W Büchler; Philipp Beckhove
Journal:  Cancer Res       Date:  2005-11-01       Impact factor: 12.701

Review 4.  Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer.

Authors:  Michael A Morse; Joseph Robert Hall; Janet M D Plate
Journal:  Expert Opin Biol Ther       Date:  2009-03       Impact factor: 4.388

5.  Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms.

Authors:  Yu Yu; Hyun-Ii Cho; Dapeng Wang; Kane Kaosaard; Claudio Anasetti; Esteban Celis; Xue-Zhong Yu
Journal:  J Immunol       Date:  2013-01-11       Impact factor: 5.422

Review 6.  Pancreatic cancer microenvironment.

Authors:  Jörg Kleeff; Philipp Beckhove; Irene Esposito; Stephan Herzig; Peter E Huber; J Matthias Löhr; Helmut Friess
Journal:  Int J Cancer       Date:  2007-08-15       Impact factor: 7.396

7.  Listeria-based cancer vaccines that segregate immunogenicity from toxicity.

Authors:  Dirk G Brockstedt; Martin A Giedlin; Meredith L Leong; Keith S Bahjat; Yi Gao; William Luckett; Weiqun Liu; David N Cook; Daniel A Portnoy; Thomas W Dubensky
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-13       Impact factor: 11.205

8.  Dynamics of the immune reaction to pancreatic cancer from inception to invasion.

Authors:  Carolyn E Clark; Sunil R Hingorani; Rosemarie Mick; Chelsea Combs; David A Tuveson; Robert H Vonderheide
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

9.  The split nature of tumor-infiltrating leukocytes: Implications for cancer surveillance and immunotherapy.

Authors:  Telma Lança; Bruno Silva-Santos
Journal:  Oncoimmunology       Date:  2012-08-01       Impact factor: 8.110

10.  Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells.

Authors:  Vivian L Weiss; Timothy H Lee; Hong Song; Theodore S Kouo; Chelsea M Black; George Sgouros; Elizabeth M Jaffee; Todd D Armstrong
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

View more
  58 in total

1.  Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer.

Authors:  Andrew J Gunderson; Megan M Kaneda; Takahiro Tsujikawa; Abraham V Nguyen; Nesrine I Affara; Brian Ruffell; Sara Gorjestani; Shannon M Liudahl; Morgan Truitt; Peter Olson; Grace Kim; Douglas Hanahan; Margaret A Tempero; Brett Sheppard; Bryan Irving; Betty Y Chang; Judith A Varner; Lisa M Coussens
Journal:  Cancer Discov       Date:  2015-12-29       Impact factor: 39.397

2.  Leveraging premalignant biology for immune-based cancer prevention.

Authors:  Avrum Spira; Mary L Disis; John T Schiller; Eduardo Vilar; Timothy R Rebbeck; Rafael Bejar; Trey Ideker; Janine Arts; Matthew B Yurgelun; Jill P Mesirov; Anjana Rao; Judy Garber; Elizabeth M Jaffee; Scott M Lippman
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-16       Impact factor: 11.205

Review 3.  Tumour-targeting bacteria engineered to fight cancer.

Authors:  Shibin Zhou; Claudia Gravekamp; David Bermudes; Ke Liu
Journal:  Nat Rev Cancer       Date:  2018-12       Impact factor: 60.716

4.  Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery.

Authors:  Jae W Lee; Chad A Komar; Fee Bengsch; Kathleen Graham; Gregory L Beatty
Journal:  Curr Protoc Pharmacol       Date:  2016-06-01

5.  Collagen I enhances the efficiency and anti-tumor activity of dendritic-tumor fusion cells.

Authors:  Jian He; Rong Zheng; Zhenghua Zhang; Jie Tan; Chaofan Zhou; Guoqing Zhang; Xinglu Jiang; Qianyi Sun; Sufang Zhou; Duo Zheng; Yong Huang; Lige Wu; Zongqiang Lai; Jieping Li; Nuo Yang; Xiaoling Lu; Yongxiang Zhao
Journal:  Oncoimmunology       Date:  2017-08-08       Impact factor: 8.110

Review 6.  Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention.

Authors:  Nina J Chu; Todd D Armstrong; Elizabeth M Jaffee
Journal:  Clin Cancer Res       Date:  2015-01-26       Impact factor: 12.531

Review 7.  Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy.

Authors:  Silvia von Karstedt; Antonella Montinaro; Henning Walczak
Journal:  Nat Rev Cancer       Date:  2017-05-24       Impact factor: 60.716

8.  Inhibition of miR-21 Regulates Mutant KRAS Effector Pathways and Intercepts Pancreatic Ductal Adenocarcinoma Development.

Authors:  Nina J Chu; Robert A Anders; Elana J Fertig; Minwei Cao; Alexander C Hopkins; Bridget P Keenan; Aleksandra Popovic; Todd D Armstrong; Elizabeth M Jaffee; Jacquelyn W Zimmerman
Journal:  Cancer Prev Res (Phila)       Date:  2020-05-14

9.  Transforming Cancer Prevention through Precision Medicine and Immune-oncology.

Authors:  Thomas W Kensler; Avrum Spira; Judy E Garber; Eva Szabo; J Jack Lee; Zigang Dong; Andrew J Dannenberg; William N Hait; Elizabeth Blackburn; Nancy E Davidson; Margaret Foti; Scott M Lippman
Journal:  Cancer Prev Res (Phila)       Date:  2016-01

10.  Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway.

Authors:  Rasha Abu-Eid; Raed N Samara; Laurent Ozbun; Maher Y Abdalla; Jay A Berzofsky; Kevin M Friedman; Mikayel Mkrtichyan; Samir N Khleif
Journal:  Cancer Immunol Res       Date:  2014-07-30       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.